Myocardial clearance kinetics of technetium-99m-SQ30217: a marker of regional myocardial blood flow
- PMID: 2362197
Myocardial clearance kinetics of technetium-99m-SQ30217: a marker of regional myocardial blood flow
Abstract
SQ30217 is a new, technetium-99m-(99mTc) labeled perfusion agent introduced for cardiac imaging. To evaluate the myocardial tracer kinetics, 99mTc-SQ30217, was injected intracoronarily in open-chested dogs under baseline conditions and after administration of intravenous (i.v.) dipyridamole. Myocardial first-pass retention fraction averaged 0.90 +/- 0.04. Clearance of the tracer occurred in a biexponential manner. Sixty-seven percent of retained activity cleared with a half-time of 2.3 +/- 0.6 min, while the residual activity demonstrated slow clearance. The clearance rate of the rapid phase correlated with myocardial blood flow (r = 0.72, p less than 0.001). Myocardial SQ30217 clearance rate following i.v. injection as determined by dynamic imaging with tomography (SPRINT) averaged 21 +/- 4 min and increased to 13 +/- 4 min following dipyridamole. Thus, 99mTc-SQ30217 is a promising flow tracer with high initial myocardial retention and rapid tissue clearance, which allow repeated flow determinations within short time intervals using advanced SPECT technology.
Similar articles
-
The effect of flow on technetium-99m-teboroxime (SQ30217) and thallium-201 extraction and retention in rabbit heart.J Nucl Med. 1991 Oct;32(10):1979-88. J Nucl Med. 1991. PMID: 1919742
-
The relationship between myocardial retention of technetium-99m teboroxime and myocardial blood flow.J Am Coll Cardiol. 1992 Sep;20(3):712-9. doi: 10.1016/0735-1097(92)90029-m. J Am Coll Cardiol. 1992. PMID: 1512353
-
Demonstration of differential post-stenotic myocardial technetium-99m-teboroxime clearance kinetics after experimental ischemia and hyperemic stress.J Nucl Med. 1991 Oct;32(10):2000-8. J Nucl Med. 1991. PMID: 1919745
-
Clinical experience with technetium-99m teboroxime, a neutral, lipophilic myocardial perfusion imaging agent.Am J Cardiol. 1990 Oct 16;66(13):63E-67E. doi: 10.1016/0002-9149(90)90614-7. Am J Cardiol. 1990. PMID: 2220625 Review.
-
Advances in myocardial perfusion imaging: 99mTc-teboroxime.J Nucl Biol Med (1991). 1992 Apr-Jun;36(2 Suppl):22-8. J Nucl Biol Med (1991). 1992. PMID: 1450239 Review. No abstract available.
Cited by
-
Comparison of thallium-201 and technetium-99m teboroxime myocardial single photon emission tomography with coronary arteriography.Eur J Nucl Med. 1992;19(7):522-6. doi: 10.1007/BF00185859. Eur J Nucl Med. 1992. PMID: 1644109
-
Myocardial clearance of technetium-99m-teboroxime in reperfused injured canine myocardium.EJNMMI Res. 2014 Aug 1;4:42. doi: 10.1186/s13550-014-0042-6. eCollection 2014. EJNMMI Res. 2014. PMID: 25411652 Free PMC article.
-
Compartmental modeling of technetium-99m-labeled teboroxime with dynamic single-photon emission computed tomography: comparison with static thallium-201 in a canine model.Invest Radiol. 2001 Mar;36(3):178-85. doi: 10.1097/00004424-200103000-00007. Invest Radiol. 2001. PMID: 11228582 Free PMC article.
-
Static Versus Dynamic Teboroxime Myocardial Perfusion SPECT in Canines.IEEE Trans Nucl Sci. 2000 Jun 1;47(3):1112-1117. doi: 10.1109/23.856556. IEEE Trans Nucl Sci. 2000. PMID: 20090867 Free PMC article.
-
Are technetium-99m-labeled myocardial perfusion agents adequate for detection of myocardial viability?Clin Cardiol. 1998 Apr;21(4):235-42. doi: 10.1002/clc.4960210402. Clin Cardiol. 1998. PMID: 9562932 Free PMC article. Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources